Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

With a market cap of $149.1 billion, Amgen Inc. (AMGN) is renowned for its innovative human therapeutics across oncology, ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc ...

Biocon Biologics on Thursday said it has received an approval from the US health regulator to market a cancer treatment biosimilar product. The company, a subsidiary of Biocon Ltd, has received ...

JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab). JOBEVNE is a vascular ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd has received U.S. Food and Drug Administration (U.S. FDA) approval for its Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

The U.S. Food and Drug Administration (U.S. FDA) has approved Biocon Biologics’ Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized ...

The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Rybelsus (semaglutide) and Ozempic (semaglutide) are prescription drugs used to treat type 2 diabetes. Rybelsus comes as an oral tablet, while Ozempic comes as an injectable liquid solution. This ...